Skip to content

April 2026

PTSD

What April 2026's 6 new studies found, synthesized from the papers below. All PTSD research →

The synthesis

Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.

Research published in April 2026 on PTSD treatments shows promising but preliminary results: a Phase 2 RCT found that four weekly doses of methylone (TSND-201) significantly reduced PTSD symptoms versus placebo, and a controlled trial reported that Transcendental Meditation markedly reduced PTSD and depression symptoms in Ukrainian refugees. However, these findings are based on small or early-phase studies, and a review of psychedelic-assisted therapy noted mild transient adverse effects but highlighted concerns about long-term safety and inconsistent adverse event reporting. Overall, the evidence is encouraging but not yet definitive, with durability and larger-scale confirmation still needed.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.

Four weekly doses of TSND-201 (methylone) significantly reduced PTSD symptoms compared with placebo, with generally mild to moderate adverse events and no significant suicidal ideation.

Phase 2 randomized controlled trial

Media coverage of psychedelics used more positive emotion and sentiment language, while coverage of antidepressants used more negative emotion and risk language, but reward language was more associated with antidepressants and negative sentiment was more associated with psychedelics.

pre-registered analysis of media coverage using natural language processing and binary logistic regressions Sample size: 6805

Regular practice of the Transcendental Meditation program was associated with rapid and statistically significant reductions in PTSD and depression symptoms, with the proportion of probable PTSD dropping from 60.0% to 2.5% after 30 days and to 0% after 60 days.

controlled trial Sample size: 80

Argues that complex PTSD involves disturbances in self-organization that may stem from dysregulation of oxytocin and vasopressin systems linked to evolutionarily ancient appeasement behaviors, but this hypothesis requires verification in human subjects.

review

Psychedelic-assisted therapy for PTSD tends to produce mild, transient adverse effects, but concerns about long-term safety and inconsistent reporting of adverse events highlight the need for further research.

review

Both mindfulness diving and a multisport program produced slight improvement in PTSD symptoms with no significant difference between groups; the multisport group showed reduced intrusions and avoidance symptoms at one to two months post-course.

controlled clinical trial Sample size: 60

Points of agreement

  • Several interventions (methylone, Transcendental Meditation, mindfulness diving, multisport) show potential to reduce PTSD symptoms.
  • Adverse effects of psychedelic-assisted therapy are generally mild and transient in the short term.
  • Media coverage of psychedelics tends to be more positive than coverage of antidepressants.

Conflicts

  • The media analysis found negative sentiment was more strongly related to psychedelics, contrary to the overall pattern of positive coverage.
  • The multisport program showed reduced intrusions and avoidance symptoms, while mindfulness diving did not show a significant difference between groups, suggesting differential effects on symptom clusters.

Gaps

  • Long-term safety and durability of effects are not established for psychedelic-assisted therapy or methylone.
  • Sample sizes are small (e.g., 80, 60) and Phase 2 trials need confirmation in larger Phase 3 studies.
  • The biomarker review hypothesis for complex PTSD requires verification in human subjects.
  • Adverse event reporting in psychedelic-assisted therapy is inconsistent, limiting safety conclusions.
  • The Transcendental Meditation trial lacks long-term follow-up beyond 60 days.
Browse these studies in the library